Virginia Tech Research Team Identifies Dual Protein Blockade That Reverses Pulmonary Fibrosis Scarring

Virginia Tech researchers find that inhibiting ID1 and ID3 proteins can reverse pulmonary fibrosis. Learn how this breakthrough could change lung disease treatment.

By: AXL Media

Published: Apr 29, 2026, 7:49 AM EDT

Source: Information for this report was sourced from EurekAlert!

A Potential Shift from Delaying to Reversing Lung Disease

Idiopathic pulmonary fibrosis remains a devastating respiratory condition characterized by the relentless buildup of scar tissue that eventually suffocates the patient. While current medical interventions can marginally slow the progression of the disease, they are unable to stop or repair existing damage. A new study published in the journal Theranostics suggests a paradigm shift in treatment by targeting two specific proteins. According to senior author Yassine Sassi, the simultaneous inhibition of these drivers not only prevented further damage in experimental systems but also demonstrated the ability to reduce established scarring and restore respiratory capacity.

Identifying the Drivers of Fibroblast Overactivity

The research focused on lung fibroblasts, which are the primary cells responsible for the formation of the thick, non-functional tissue that defines fibrosis. By analyzing human lung tissue from patients with the disease, the Virginia Tech team found that levels of the proteins ID1 and ID3 were significantly elevated compared to healthy lungs. These proteins act as biological switches that keep fibroblasts in a state of hyper-activation. According to the study, when these proteins are present in high concentrations, they force the lung tissue to undergo a transformation into rigid scar tissue, a process that has historically been considered irreversible.

Disrupting the Cellular Pathways of Scarring

The study provides detailed insight into the molecular mechanisms that these proteins exploit to damage the lungs. ID1 and ID3 regulate growth through specific cell cycle pathways and promote the scarring process via MEK/ERK signaling. These are the fundamental instructions that tell cells to multiply and produce excess collagen. According to the research team, by targeting these specific pathways, they can effectively interrupt the cellular commands that drive the fibrotic process. This targeted approach ensures that the therapy addresses the root cause of the scarring rather than just managing the resulting inflammation or symptoms.